Perioperative fluvastatin reduced cardiac events after noncardiac vascular surgery

Al-Shoaibi, Naeem; Massel, David
January 2010
ACP Journal Club;1/19/2010, Vol. 152 Issue 1, p6
Academic Journal
The article discusses a study conducted by researcher D. Poldermans and colleagues to know whether perioperative fluvastatin reduces risk for adverse cardiac events after noncardiac vascular surgery. Randomized placebo-controlled trial conducted on 497 patients found that myocardial ischemia and a composite of death from cardiovascular causes and nonfatal myocardial infarction can be reduced by perioperative fluvastatin after noncardiac vascular surgery.


Related Articles

  • Atorvastatin Reload Prior to PCI for Patients on Chronic Statin Therapy. Boyle, Andrew J. // Clinical Cardiology Alert;Oct2009, Vol. 28 Issue 10, p73 

    The article discusses the study "Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial." The study aimed to...

  • The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].  // BMC Medicine;2005, Vol. 3, p6 

    Background: There have been concerns that low blood cholesterol concentrations may cause nonvascular mortality and morbidity. Randomisation of large numbers of people to receive a large, and prolonged, reduction in cholesterol concentrations provides an opportunity to address such concerns...

  • One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Hansteen, V.; Moinichen, E.; Lorentsen, E.; Strom, O.; Soiland, K.; Dyrbekk, D.; Refsum, A.-M.; Tromsdal, A.; Knudsen, K.; Eika, C.; Jun, J. Bakken; Smith, P.; Hoff, P.I. // British Medical Journal (Clinical Research Edition);1/16/1982, Vol. 284 Issue 6310, p155 

    Investigates the effects of propranolol and placebo on patients with history of myocardial infarction in Norway. Rate of mortality; Reduction in sudden cardiac deaths among high risk patients treated with propanol; Benefits of long-term beta-adrenoceptor blockade in low-risk patients.

  • Calcium supplementation and vascular events.  // Practical Neurology;Apr2008, Vol. 46 Issue 4, p134 

    The article reports on the result of a randomised, placebo controlled trial from New Zealand, which evaluated 1471 postmenopausal women. The study revealed that calcium supplementation in healthy postmenopausal women is related to an increase in vascular event rates. It also showed that the...

  • Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Deedwania, Prakash C.; Ahmed, Mustafa I.; Feller, Margaret A.; Aban, Inmaculada B.; Love, Thomas E.; Pitt, Bertram; Ahmed, Ali // European Journal of Heart Failure;May2011, Vol. 13 Issue 5, p551 

    Aims To determine independent associations of diabetes mellitus with outcomes in a propensity-matched cohort of patients with acute myocardial infarction (AMI) and systolic heart failure (HF). Methods and results In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and...

  • Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease? Doggrell, Sheila Anne // Reviews on Recent Clinical Trials;May2011, Vol. 6 Issue 2, p147 

    As coronary artery disease (CAD) remains a leading cause of death in the world, the development of anticoagulants to prevent CAD progressing to myocardial infarction and death is a high priority. A number of direct Factor Xa (FXa) inhibitors are being developed for use in CAD. Despite being...

  • Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29 

    The article presents information on the method adopted to treat patients with acute ST-segment elevation myocardial infarction. The objective was to find out the effect of the drug fondaparinux in reducing reinfarction or death in patients. Randomized placebo-controlled trial was carried out on...

  • Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: Effect of noncompliance. Cook, Nancy; Cole, Stephen; Buring, Julie // European Journal of Epidemiology;Jun2012, Vol. 27 Issue 6, p431 

    Randomized evidence for aspirin in the primary prevention of cardiovascular disease (CVD) among women is limited and suggests at most a modest effect for total CVD. Lack of compliance, however, can null-bias estimated effects. We used marginal structural models (MSMs) to estimate the etiologic...

  • Hepatic Findings in Long-Term Clinical Trials of Ximelagatran. Lee, William M.; Larrey, Dominique; Olsson, Rolf; Lewis, James H.; Keisu, Marianne; Auclert, Laurent; Sheth, Sunita // Drug Safety;2005, Vol. 28 Issue 4, p351 

    Objective: In clinical trials, the efficacy and safety of the oral direct thrombin inhibitor ximelagatran have been evaluated in the prevention or treatment of thromboembolic conditions known to have high morbidity and mortality. In these studies, raised aminotransferase levels were observed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics